ALNY: Brezosiran showed robust early HTT lowering; a pivotal study is planned for 2027

What happened

Initial phase Ib data for brezosiran showed dose-dependent reductions of 60%-64% in CSF HTT at month 3, with no reported dose-dependent signals in inflammation, neurofilament or ventricular volume, and a pivotal placebo-controlled study is planned for 2027, pending regulatory alignment.

Confirmed

Global impact / market context

A 60%-64% reduction in the disease-related protein at month 3 suggests the drug is hitting its intended biological target, which supports advancing to a larger placebo-controlled trial and could raise expectations for future revenue if the approach succeeds in later testing.

Analyst inference

Investors in Alnylam now weigh early biological signals against the long path to approval, because the pivotal study is planned for 2027 and depends on regulatory alignment; trial timing and later results, not the phase Ib data alone, will drive expectations.

Analyst inference

What to watch

1. Watch for regulatory alignment on the planned pivotal placebo-controlled study, because that agreement must happen before the 2027 trial can proceed as described. Confirmed
2. Watch whether the company announces the pivotal study design, including patient numbers and endpoints, which would clarify the cost and timeline of the larger trial. Proposed
3. Watch later trial data for whether the protein reduction translates into clinical benefit, since early biomarker gains do not guarantee that the drug improves patient outcomes. Analyst inference

Evidence

• Original source link unavailable